medigraphic.com
ISSN 1561-2988 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Farm 2022; 55 (2)

Consumption of ivermectin for the treatment and prevention of COVID-19 in Peru

Iglesias-Osores S, Acosta-Quiroz J, Yamunaqué-Carranza M, Córdova-Rojas LM, Mendoza-Gastelo GJ, Mendoza-Gastelo GJ, Colmenares-Mayanga W, Becerra-Atoche G, Ruiz-Torres C

Language: Spanish
References: 27
Page: 1-12
PDF size: 668.86 Kb.


ABSTRACT

Introduction: The use of ivermectin in the treatment or prevention against COVID-19 poses a public health problem.
Objective: Describe the inappropriate use of ivermectin for the treatment and prevention of COVID-19.
Methods: Prospective cross-sectional study. A snowball-type sampler was used. All those who agreed to participate in the study (163) and who agreed to participate voluntarily were interviewed. The participants belonged to the departments of Áncash, Apurímac, Arequipa, Ayacucho, Cajamarca, Callao, Cusco, Huancavelica, Huánuco, Ica, Junín, La Libertad, Lambayeque, Lima, Pasco, Piura, Puno, Tacna and Ucayali (Peru). The study was conducted during the month of May, 2021.
Results: 163 participants were surveyed, of which 71 (44%) were men and 92 (56%) women, with a mean age of 56.41 (SD 10.24) and with a minimum of 21 and a maximum of 82 years. The most relevant was the frequent use of ivermectin for the spread of COVID-19, although it was consumed more time by people who used it as prevention method.
Conclusions: People consumed ivermectin once or twice a day, without a prescription, as prevention or because they had COVID-19. Those who took it as a preventive method took high doses for a long time putting their health at risk. This situation could be reversed through the proper implementation of science-based directives and a better media information policy.


REFERENCES

  1. Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality inpatients with COVID-19: A systematic review, meta-analysis, and meta-regression ofrandomized controlled trials. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102186. DOI:10.1016/j.dsx.2021.102186

  2. Jean SS, Hsueh PR. Old and re-purposed drugs for the treatment of COVID-19. ExpertRev Anti Infect Ther. 2020;18(9):843-7. DOI: 10.1080%2F14787210.2020.1771181

  3. Esquén Leyva C, Hashimoto Pacheco H, Esquén Leyva C, Hashimoto Pacheco H.Seguridad farmacológica de la ivermectina vía oral en gestantes. Rev Peru Ginecol y Obstet.2020;66(4):00005. DOI: 10.31403/rpgo.v66i2285

  4. Parveen M, Molla MMA, Yeasmin M, Nafisa T, Barna AA, Ghosh AK. Evidences onirrational anti-microbial prescribing and consumption among COVID-19 positive patientsand possible mitigation strategies: a descriptive cross sectional study. Bangladesh J InfectDis. 2020;7(00):S3-S7. DOI: 10.3329/bjid.v7i00.50155

  5. Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, et al. Ivermectinfor preventing and treating COVID-19. Cochrane Database Syst Rev. 2021;7(7):CD015017.DOI: 10.1002/14651858.cd015017.pub2

  6. Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A comprehensivereview of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. FrontImmunol. 2021;12:631139. DOI: 10.3389/fimmu.2021.631139

  7. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin forprevention and treatment of COVID-19 infection: a systematic review, meta-analysis, andtrial sequential analysis to inform clinical guidelines. Am J Ther. 2021 [acceso03/11/2021];28(4):e434-60. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34145166/

  8. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drugivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 [acceso03/11/2021];178:104787.

  9. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety,tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adultsubjects. J Clin Pharmacol. 2002;42(10):1122-33. DOI: 10.1177/009127002401382731

  10. Peña‐ Silva R, Duffull SB, Steer AC, Jaramillo‐ Rincon SX, Gwee A, Zhu X.Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. Br J Clin Pharmacol. 2021 [acceso 03/11/2021];87(3):1589-90. DOI: 10.111/bcp.14476

  11. Consortium WST. Repurposed antiviral drugs for COVID-19. Interim WHO solidaritytrial results; 2020;384(6):497-511. DOI: 101056/nejmoa2023184

  12. Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviewson ivermectin for COVID-19. BMJ Evidence-Based Med. 2021;bmjebm-2021-111678.DOI: 10.1136/bmjebm-2021-111678

  13. Gobierno del Perú. Resolución Ministerial N° 270-2020-MINSA. Prevención,Diagnóstico y Tratamiento de personas afectadas por COVID-19. Perú: MINSA; 2020[acceso 03/11/2021]. Disponible en: https://www.gob.pe/institucion/minsa/normaslegales/563764-270-2020-minsa

  14. Lescano J, Pinto C. Ivermectina dentro del protocolo de tratamiento para la COVID-19en Perú: Uso sin evidencia científica. Salud y Tecnol Vet. 2020;8(1):27-34. DOI:10.20453/stv.v8i1.3789

  15. OMS. La OMS desaconseja usar ivermectina para tratar la COVID-19 si no es en ensayosclínicos. Ginebra: OMS; 2021 [acceso 03/11/2021]. Disponible en: https://n9.cl/xn7e9

  16. Johnson-Arbor K. Ivermectin: a mini-review. Clin Toxicol. 2022;60(5):571-5. DOI:10.1080/15563650.2022.2043338

  17. Domingo-Echaburu S, Orive G, Lertxundi U. Ivermectin & COVID-19: Let’s keep aOne Health perspective. Sustain Chem Pharm. 2021;21(2021):100438. DOI:10.1016/j.scp.2021.100438

  18. Verma AK, Pandey AK, Singh A, Bajpai J, Kant S, Bajaj DK. Assessing knowledge,attitude, and practices towards ivermectin pre-exposure prophylaxis for COVID-19 amongHealth Care Workers. Indian J Community Heal. 2021 [acceso 03/11/2021];33(3):430-4.Disponible en: https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/2221

  19. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin andazithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes NewInfect. 2020;35(2020):100684. DOI: 10.1016/j.nmni.2020.100684

  20. Echeverría-Esnal D, Grau S. Ivermectin: a pathway out of the pandemic or another deadend? Expert Rev Anti Infect Ther. 2021;1-3. DOI: 10.1080/14787210.2022.2012154

  21. Ramírez C, Herrera-Paz EF, Peralta G, Rodríguez G, Durón RM. Is ivermectin ready tobe part of a public health policy for COVID-19 prophylaxis? E Clinical Medicine. 2021[acceso 03/11/2021];32:100744. Disponible en:http://www.thelancet.com/article/S2589537021000249/fulltext

  22. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects toCOVID-19 complementary regimen. J Antibiot (Tokyo). 2020 [acceso03/11/2021];73(9):593-602. Disponible en: https://www.nature.com/articles/s41429-020-0336-z

  23. Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, et al. Serious IvermectinToxicity and Human ABCB1 Nonsense Mutations. N Engl J Med. 2020 [acceso03/11/2021];383(8):787-9. Disponible en:https://www.nejm.org/doi/full/10.1056/NEJMc1917344

  24. Morgenstern J, Redondo JN, Olavarria A, Rondon I, Roca S, Leon A De, et al. Ivermectinas a SARS-CoV-2 Pre-exposure prophylaxis method in healthcare workers: a propensityscore-matched retrospective cohort study. Cureus. 2021 [acceso 03/11/2021];13(8):e17455.Disponible en: https://n9.cl/adwyg

  25. Kazi SE, Akhter S, Periasamy D, Faruki F, Tahir R. Acute psychosis and COVID-19infection: psychiatric symptoms in hospitalized patients. Cureus. 2021 [acceso03/11/2021];13(9):e18121. Disponible en: https://www.cureus.com/articles/70524-acutepsychosis-and-COVID-19-infection-psychiatric-symptoms-in-hospitalized-patients

  26. Scarella TM, Laferton JAC, Ahern DK, Fallon BA, Barsky A. The relationship ofhypochondriasis to anxiety, depressive, and somatoform disorders. Psychosomatics.2016;57(2):200-7. DOI: 10.1016/j.psym.2015.10.006

  27. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectinfor the treatment of coronavirus disease 2019: A systematic review and meta-analysis of randomized controlled Trials. Clin Infect Dis. 2021 [acceso 03/11/2021];74(6):1022-9. DOI:10.1093/cid/ciab591




2020     |     www.medigraphic.com